Vir Biotechnology (VIR) Income from Continuing Operations (2018 - 2025)
Historic Income from Continuing Operations for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to -$163.1 million.
- Vir Biotechnology's Income from Continuing Operations rose 2366.49% to -$163.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$499.7 million, marking a year-over-year increase of 631.69%. This contributed to the annual value of -$522.0 million for FY2024, which is 1514.46% up from last year.
- Vir Biotechnology's Income from Continuing Operations amounted to -$163.1 million in Q3 2025, which was up 2366.49% from -$111.0 million recorded in Q2 2025.
- Over the past 5 years, Vir Biotechnology's Income from Continuing Operations peaked at $525.3 million during Q4 2021, and registered a low of -$213.7 million during Q3 2024.
- Its 5-year average for Income from Continuing Operations is -$25.7 million, with a median of -$111.0 million in 2025.
- In the last 5 years, Vir Biotechnology's Income from Continuing Operations soared by 54975.38% in 2021 and then tumbled by 22374.9% in 2022.
- Quarter analysis of 5 years shows Vir Biotechnology's Income from Continuing Operations stood at $525.3 million in 2021, then crashed by 119.34% to -$101.6 million in 2022, then fell by 14.14% to -$116.0 million in 2023, then rose by 9.82% to -$104.6 million in 2024, then crashed by 55.98% to -$163.1 million in 2025.
- Its Income from Continuing Operations stands at -$163.1 million for Q3 2025, versus -$111.0 million for Q2 2025 and -$121.0 million for Q1 2025.